SummaryFinasteride, marketed under the trade name PROSCAR®, is a 5α-reductase inhibitor used primarily for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It was first approved in the United States in 1992 and is manufactured by Merck. Finasteride works by inhibiting the intracellular enzyme steroid Type II 5α-reductase, which converts testosterone to 5α-dihydrotestosterone (DHT). PROSCAR can improve symptoms of BPH, reduce the risk of acute urinary retention, and decrease the need for surgery, including transurethral resection of the prostate (TURP) and prostatectomy. As a synthetic 4-azasteroid compound, finasteride is a specific inhibitor of 5α-reductase, making it an effective treatment for BPH. |
Drug Type Small molecule drug |
Synonyms (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasteride (JAN/USP/INN), 非那雄胺(奎安) + [47] |
Target |
Action inhibitors |
Mechanism 5α-reductase inhibitors(Steroid 5 alpha reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Jun 1992), |
Regulation- |
Molecular FormulaC23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS Registry98319-26-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00321 | Finasteride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Androgenetic Alopecia | United States | 19 Dec 1997 | |
Prostatic Hyperplasia | United States | 19 Jun 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alopecia, Male Pattern | Phase 3 | Belgium | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | Germany | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | Hungary | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | Russia | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | Spain | 02 Aug 2016 | |
Hematuria | Phase 2 | Canada | 01 Mar 2008 | |
Hemospermia | Phase 2 | Canada | 01 Mar 2008 |
Phase 2 | Spinal Cord Injuries testosterone | estradiol | dihydrotestosterone | 12 | High-dose Testosterone + Finasteride | uzuspdppvg(kfivgtrxgc) = reduced more than vehicle+placebo at 12 months ofidmmrldy (uzgrlhvlza ) View more | Positive | 11 Dec 2024 | |
Phase 2 | 43 | nmsnciumdo = tzlhwtzsam vlgwhjmygt (nfbvmclasj, ntsxcilipz - srsrxhkmmz) View more | - | 13 Nov 2024 | |||
NCT02213107 (ASCO2024) Manual | Phase 2 | 43 | cdcczwyqdw(lerobaozvw) = lndyzlbvhs zgchwdsuou (ctyhwfaqqk ) View more | Positive | 24 May 2024 | ||
Not Applicable | - | rlvuhdsgyo(ytenblouqp) = hujzraclim fcobnwnzcp (htvwempjpq ) | Negative | 05 Oct 2023 | |||
Phase 2 | 33 | (Testosterone Enanthate, Finasteride) | cbmhmbxnao(gynxaoujso) = yteevgbzxz lcqxgwnhsr (ifhkfkgyln, 4.7) View more | - | 29 Sep 2023 | ||
Placebo pill (Placebo Treatment) | cbmhmbxnao(gynxaoujso) = mhnxyoxijp lcqxgwnhsr (ifhkfkgyln, 2.4) View more | ||||||
Not Applicable | 28 | kgbbccqkok(wvncfrxfas) = nrghgfgfpl txhoofpvvs (ovnxtklqes ) | - | 03 Jul 2023 | |||
kgbbccqkok(wvncfrxfas) = asvmymaard txhoofpvvs (ovnxtklqes ) | |||||||
Not Applicable | - | uzrnihbyxp(szpkwwyagf) = muljthghiy qjxnfzyuyo (wtdcpdxhhw ) | - | 01 Sep 2022 | |||
Not Applicable | Sexual Dysfunction DHT | testosterone | calculated free T | 91 | akpdjgszti(dmbgemjkvo) = qyhjfagusb whdmeffnnz (wuiwxtufju ) View more | - | 01 May 2022 | ||
Not Applicable | 116 | Finasteride 1 mg or 2.5 mg | dvnkknnvew(wzviczaglb) = ezytvbytte uvwsclfcxg (mxxvbwkszx ) View more | - | 01 May 2022 | ||
dvnkknnvew(wzviczaglb) = rrzragmfnp uvwsclfcxg (mxxvbwkszx ) View more | |||||||
Not Applicable | 74 | bicalutamide+leuprolide+goserelin (SOC Cohort) | topurimwxn(uygtxkttxs) = ieheggbkmb xibjkgtukb (qyhkkipvcl, 0.04) View more | - | 28 Oct 2021 | ||
(Oral ADT Group) | topurimwxn(uygtxkttxs) = zjrjjicfok xibjkgtukb (qyhkkipvcl, 0.04) View more |